HIF1A and breast carcinoma: Vandetanib, a FDA-approved medullary thyroid cancer therapy that inhibits EGFR (22), impairs the HIF-1 pathway by targeting the mTOR–HIF-1α–VEGF signaling axis in breast cancer cells (23) and increases survival in advanced medullary thyroid carcinoma (268).